A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India
Фаза 3
Завершено
NCT06060067
| Заболевание | Healthy Volunteers |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Takeda |
|---|
| Статус | Завершено |
|---|
| Участники | 480 участн. |
|---|
| Вмешательство | TDV |
|---|
| Дата начала | 29.03.2024 |
|---|
| Дата завершения | 5.05.2025 |
|---|
| Публикация результатов | 29.05.2026 |
|---|
Кратко
The main aims of the study are to learn about side effects and a participant's immune response to Takeda's Dengue Vaccine when given twice within 3 months. Participants will receive 2 doses of their randomized treatment (vaccine or placebo). Children, teenagers and adults will receive one dose of either the vaccine or placebo on Day 1 and the second dose of either the vaccine or placebo 3 months later. Up to 4 blood samples will be taken throughout the study. During the study, participants will visit their study clinic 6 times.
Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) by Severity Within 7 Days Post-vaccination at Day 1 for Age Group Less Than 6 Years
Within 7 days post-vaccination at Day 1 · Participants
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 42 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 10 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 4 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 4 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 0 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 0 Participants |
|---|
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 1 for Age Group 6 Years and Over
Within 7 days post-vaccination at Day 1 · Participants
| Cohort 1: ≥18 to ≤60 Years Age Group: TDV | 152 Participants |
|---|
| Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | 53 Participants |
|---|
| Cohort 2: ≥6 to <18 Years Age Group: TDV | 119 Participants |
|---|
| Cohort 2: ≥6 to <18 Years Age Group: Placebo | 42 Participants |
|---|
| Cohort 1: ≥18 to ≤60 Years Age Group: TDV | 25 Participants |
|---|
| Cohort 1: ≥18 to ≤60 Years Age Group: Placebo | 7 Participants |
|---|
Number of Participants With Solicited Local (Injection Site) AEs by Severity Within 7 Days Post-vaccination at Day 90 for Age Group Less Than 6 Years
Within 7 days post-vaccination at Day 90 · Participants
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 44 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 14 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 2 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 0 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: TDV | 0 Participants |
|---|
| Cohort 2: ≥4 to <6 Years Age Group: Placebo | 0 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.